March 22, 2019
Neurotrope jumps in the Alzheimer’s solution chase, amid Biogen’s, Eisai’s dropping aducanunab trial
Neurotrope said Friday, commenting Biogen Inc.’s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer’s disease, Phase 2 clinical trial using its drug Bryostatin during the second half of 2019.
